Latent tuberculosis in children and youth with type 1 diabetes mellitus in Dar es Salaam, Tanzania: a cross section survey.
Children
Diabetes
Glycaemic
Latent tuberculosis
QuantiFERON
T1DM
Youth
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
received:
10
03
2023
accepted:
25
10
2023
medline:
1
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
Data for latent tuberculosis in patients with type 1 Diabetes in Africa is limited. We assessed the prevalence of latent tuberculosis in youth and children with type 1 Diabetes in Dar es Salaam -Tanzania. Our cross-sectional study recruited children and youth with T1DM by stage of puberty, glycaemic control, and age at diagnosis from January to December 2021 in Dar es Salaam. Participants were screened for the presence of latent Tuberculosis using the QuantiFERON test. A positive test was considered to have latent TB. Of the 281 participants, the mean age was 19 (± 6) years, 51.2% were female, and 80.8% had either a primary or secondary level of education at baseline. The prevalence of latent TB was 14.9% and was slightly higher in females (52.4%) than in males. This difference, however, was insignificant (p > 0.05). On the other hand, the proportion of latent TB was significantly higher in uncontrolled HbA1c levels (76.2%) than in those with controlled HbA1c (23.8%) [p = 0.046]. Duration of diabetes and age at diagnosis did not affect the occurrence of latent Tuberculosis [p > 0.05]. Meanwhile, in the regression model, participants with latent TB were more likely to have uncontrolled HbA1c. [p = 0.045] CONCLUSIONS: Despite the methodological limitations, this survey highlights the high prevalence of latent TB among children and youth with diabetes; shouting for better control. These results clearly show the need to screen for Tuberculosis in children and youth with diabetes and start them on prevention as per protocol, especially in tuberculosis-endemic areas like Tanzania.
Sections du résumé
BACKGROUND
BACKGROUND
Data for latent tuberculosis in patients with type 1 Diabetes in Africa is limited. We assessed the prevalence of latent tuberculosis in youth and children with type 1 Diabetes in Dar es Salaam -Tanzania.
METHODS
METHODS
Our cross-sectional study recruited children and youth with T1DM by stage of puberty, glycaemic control, and age at diagnosis from January to December 2021 in Dar es Salaam. Participants were screened for the presence of latent Tuberculosis using the QuantiFERON test. A positive test was considered to have latent TB.
RESULTS
RESULTS
Of the 281 participants, the mean age was 19 (± 6) years, 51.2% were female, and 80.8% had either a primary or secondary level of education at baseline. The prevalence of latent TB was 14.9% and was slightly higher in females (52.4%) than in males. This difference, however, was insignificant (p > 0.05). On the other hand, the proportion of latent TB was significantly higher in uncontrolled HbA1c levels (76.2%) than in those with controlled HbA1c (23.8%) [p = 0.046]. Duration of diabetes and age at diagnosis did not affect the occurrence of latent Tuberculosis [p > 0.05]. Meanwhile, in the regression model, participants with latent TB were more likely to have uncontrolled HbA1c. [p = 0.045] CONCLUSIONS: Despite the methodological limitations, this survey highlights the high prevalence of latent TB among children and youth with diabetes; shouting for better control. These results clearly show the need to screen for Tuberculosis in children and youth with diabetes and start them on prevention as per protocol, especially in tuberculosis-endemic areas like Tanzania.
Identifiants
pubmed: 37904143
doi: 10.1186/s12879-023-08753-4
pii: 10.1186/s12879-023-08753-4
pmc: PMC10614349
doi:
Substances chimiques
Glycated Hemoglobin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
740Informations de copyright
© 2023. The Author(s).
Références
Aten Primaria. 1995 Jul-Aug;16(3):154-7
pubmed: 7647211
BMC Infect Dis. 2019 Oct 29;19(1):915
pubmed: 31664936
Int J Tuberc Lung Dis. 2009 Jul;13(7):868-74
pubmed: 19555537
Trop Med Int Health. 2018 Oct;23(10):1058-1070
pubmed: 30062731
Int J Endocrinol. 2015;2015:761759
pubmed: 26494998
Eur Respir J. 2015 Dec;46(6):1563-76
pubmed: 26405286
Afr Health Sci. 2018 Dec;18(4):884-890
pubmed: 30766551
Can J Infect Dis Med Microbiol. 2018 Mar 06;2018:3524926
pubmed: 29692873
East Afr Health Res J. 2018;2(1):29-32
pubmed: 34308172
Int J Tuberc Lung Dis. 2006 Jun;10(6):696-700
pubmed: 16776459
Infect Dis Poverty. 2016 Mar 21;5:22
pubmed: 27009088
BMJ Open Diabetes Res Care. 2015 Aug 28;3(1):e000112
pubmed: 26336610
Lancet Infect Dis. 2009 Dec;9(12):737-46
pubmed: 19926034
Int J Tuberc Lung Dis. 2006 Sep;10(9):1036-40
pubmed: 16964797
Exp Clin Endocrinol Diabetes. 2014 Oct;122(9):528-32
pubmed: 25003362
J Infect Dis. 2016 Apr 1;213(7):1163-72
pubmed: 26609005
BMC Public Health. 2007 Sep 06;7:234
pubmed: 17822539
Scand J Infect Dis. 2008;40(11-12):888-93
pubmed: 18728934
Epidemiol Infect. 2015 Jun;143(8):1731-41
pubmed: 25274036
J Epidemiol Community Health. 2012 Jun;66(6):519-23
pubmed: 21109542
PLoS One. 2021 Jun 7;16(6):e0252808
pubmed: 34097715
World J Diabetes. 2017 Sep 15;8(9):429-435
pubmed: 28989569
BMC Endocr Disord. 2016 May 31;16(1):29
pubmed: 27246505
Trans R Soc Trop Med Hyg. 2017 Feb 1;111(2):81-89
pubmed: 28419376
Clin Infect Dis. 2017 Mar 15;64(6):719-727
pubmed: 27986673
Front Immunol. 2020 Sep 10;11:2006
pubmed: 33013856
Diabetes Care. 2007 Sep;30(9):2187-92
pubmed: 17563337
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Ann Palliat Med. 2020 Mar;9(2):152-162
pubmed: 32268768
Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1:S27-36
pubmed: 22701840
Diabetes Care. 2004 Jul;27(7):1584-90
pubmed: 15220232